Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: A randomized open label trial

Summary: Evaluated everolimus stents (2nd generation) versus paclitaxel stents (1st generation) in patients with coronary disease undergoing percutaneous coronary intervention (PCI). The primary composite endpoint of major adverse cardiac events (including cardiac death, nonfatal MI, and target vessel revascularization) was reduced by everolimus stents. There was less in-stent thrombosis with everolimus stents even though fewer patients in this arm were on dual antiplatelet therapy.

Original Publication:

J Am Coll Cardiol. 2011 Jun 28